GLOW blend (BPC-157 + TB-500 + GHK-Cu)

Skin & Cosmetic · listed as GLOW

No controlled study, in humans or animals, has evaluated the three-way combination of BPC-157, the TB-500 fragment and GHK-Cu. The only combination data located is a 2026 rat Achilles-tendon study of BPC-157 plus TB-500 (without GHK-Cu), in which the pair did not outperform either peptide alone. Evidence for each component is summarised in its own entry; none of the components has a completed, published human randomised trial for the marketed form (GHK-Cu human data are topical only). FDA has listed all three components (BPC-157, TB-500 fragment, injectable GHK-Cu) under its Category 2 safety statements citing immunogenicity/impurity concerns and limited or absent human safety data.

No combined trials1 reported adverse effect0 documented interactions3 references

🔬 Research use only — not for human or veterinary use. The regimens below are records of what published studies administered to their own subjects; they are not instructions and K4 Elite does not provide dosing instructions.

Published trial usage Adverse effects Interactions Contraindications References

Published trial usage

No controlled studies of this combination exist

No randomised, controlled or otherwise comparative study of this multi-component preparation as a combination has been published, in humans or in animals. There is therefore no trial regimen, no combined safety dataset and no interaction dataset to report for the blend itself.

What has been published concerns the individual components, each of which has its own record:

BPC-157Preclinical only TB-500 (Thymosin beta-4 fragment, Ac-LKKTETQ)Preclinical only GHK-Cu (glycyl-L-histidyl-L-lysine copper complex)Human (small/observational)

Reported adverse effects

Effects recorded in the cited reports. Frequencies are those the source reported, in the population that source studied.

Effect	Frequency / context	Source
No adverse-event data exist for the combination	No trial of the three-component blend has been conducted; component-level safety data (mostly animal, plus small topical/ocular human trials of full-length thymosin beta-4 and topical GHK-Cu) are in the individual entries.	FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks ↗

Interactions

No interactions with a verifiable citation have been indexed for this compound.

Contraindications noted in trials

Exclusions and label contraindications recorded in the cited sources.

None established for the combination. FDA Category 2 statements cover BPC-157, the thymosin beta-4 fragment (TB-500) and injectable GHK-Cu individually, each citing immunogenicity risk from aggregation and peptide-related impurities and limited or no human safety data. Source ↗

References

Elsewhere on K4 Elite

GLOW Blend (BPC-157 · TB-500 · GHK-Cu) — Peptide Research Library All indexed compounds — Research Trials

Research use only. This record summarises published literature for reference. It is not medical advice, not a protocol, and not a recommendation to administer this compound to any subject. Regimens are reported as the historical record of how a cited study was conducted; findings are reported without interpretation and constitute no claim of safety or efficacy. Determining any research procedure is the sole responsibility of the qualified researcher. Products referenced on this site are supplied strictly for in-vitro laboratory and research purposes, are not for diagnostic or therapeutic use, and have not been evaluated by the FDA.